Communiqués PTC Therapeutics, Inc.

Actions

PTCT

US69366J2006

Produits pharmaceutiques

Temps réel estimé Cboe BZX 19:57:50 17/09/2026			Varia. 5j.	Varia. 1 janv.
67,30 ^USD	-0,44%		+0,03%	-11,28%

15/09	Transcript : PTC Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 09:15 AM
24/08	PTC Therapeutics annonce de nouvelles données sur le Sephience confirmant des bénéfices cliniques étendus, notamment un contrôle métabolique durable, une libéralisation du régime alimentaire et un profil de sécurité favorable constant	CI

Communiqués

27/08	PTC Therapeutics to Participate in Upcoming Investor Conferences	PR
24/08	PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile	PR
30/07	PTC Therapeutics: Q2 Earnings Snapshot	AQ
30/07	PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results	PR
17/06	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
16/06	PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes	PR
15/06	PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes	PR
10/05	PTC Therapeutics : Corporate Presentation – May 2026	PU
08/05	PTC Therapeutics : Q1 2026 FLS	PU
08/05	PTC Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	PTC Therapeutics: Q1 Earnings Snapshot	AQ
07/05	PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results	PR
04/05	PTC Therapeutics to Participate in Upcoming Investor Conferences	PR
28/04	PTC Therapeutics : PIVOT-HD Long-Term Extension Study Topline Results Call – April 28, 2026	PU
28/04	PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam	PR
28/04	PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study	PR
22/04	PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026	PR
17/04	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
25/03	PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors	PR
13/03	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
23/02	PTC Therapeutics to Participate at Upcoming Investor Conferences	PR
19/02	PTC Therapeutics: Q4 Earnings Snapshot	AQ
19/02	PTC Therapeutics : Corporate Presentation – February 2026	PU
19/02	PTC Therapeutics : Q4 2025 FLS	PU
19/02	PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results	PR